期刊文献+

Protective Effects of Trimetazidine on Bone Marrow Mesenchymal Stem Cells Viability in an ex vivo Model of Hypoxia and in vivo Model of Locally Myocardial Ischemia 被引量:8

Protective Effects of Trimetazidine on Bone Marrow Mesenchymal Stem Cells Viability in an ex vivo Model of Hypoxia and in vivo Model of Locally Myocardial Ischemia
下载PDF
导出
摘要 Bone marrow mesenchymal stem cells (MSCs) have shown potential for cardiac repair following myocardial injury,but this approach is limited by their poor viability after transplantation.The present study was to investigate whether trimetazidine (TMZ) could improve survival of MSCs in an ex vitro model of hypoxia,as well as survival,differentiation,and subsequent activities of transplanted MSCs in rat hearts with acute myocardial infarction (AMI).MSCs at passage 3 were examined for their viability and apoptosis under a transmission electron microscope,and by using flow cytometry following culture in serumfree medium and exposure to hypoxia (5% CO2,95% N2) for 12 h with or without TMZ.Thirty Wistar rats were divided into 3 groups (n=10 each group),including groupⅠ(AMI control),groupⅡ (MSCs transplantation alone),and group Ⅲ (TMZ+MSCs).Rat MSCs (4×107) were injected into peri-infarct myocardium (MSCs group and TMZ+MSCs group) 30 min after coronary artery ligation.The rats in TMZ+MSCs group were additionally fed on TMZ (2.08 mg?kg-1?day-1) from day 3 before AMI to day 28 after AMI.Cardiac structure and function were assessed by echocardiography at 28th day after transplantation.Blood samples were collected before the start of TMZ therapy (baseline),and 24 and 48 h after AMI,and inflammatory cytokines (CRP,TNF-α) were measured.Then the sur-vival and differentiation of transplanted cells in vivo were detected by immunofluorescent staining.The cellular apoptosis in the peri-infarct region was detected by using TUNEL assay.Furthermore,apoptosis-related proteins (Bcl-2,Bax) within the post-infarcted myocardium were detected by using Western blotting.In hypoxic culture,the TMZ-treated MSCs displayed a two-fold decrease in apoptosis under serumfree medium and hypoxia environment.In vivo,cardiac infarct size was significantly reduced,and cardiac function significantly improved in MSCs and TMZ+MSCs groups as compared with those in the AMI control group.Combined treatment of TMZ with MSCs implantation demonstrated further decreased MSCs apoptosis,further increased MSCs viability,further decreased infarct size,and further improved cardiac function as compared with MSCs alone.The baseline levels of inflammatory cyto-kines (CRP,TNF-α) had no significant difference among the groups.In contrast,all parameters at 24 h were lower in TMZ+MSCs group than those in MSCs group.Furthermore,Western blotting indicated that the expression of antiapoptotic protein Bcl-2 was upregulated,while the proapoptotic protein Bax was down-regulated in the TMZ+MSCs group,compared with that in the MSCs group.It is suggested that implantation of MSCs combined with TMZ treatment is superior to MSCs monotherapy for MSCs viability and cardiac function recovery. Bone marrow mesenchymal stem cells (MSCs) have shown potential for cardiac repair following myocardial injury,but this approach is limited by their poor viability after transplantation.The present study was to investigate whether trimetazidine (TMZ) could improve survival of MSCs in an ex vitro model of hypoxia,as well as survival,differentiation,and subsequent activities of transplanted MSCs in rat hearts with acute myocardial infarction (AMI).MSCs at passage 3 were examined for their viability and apoptosis under a transmission electron microscope,and by using flow cytometry following culture in serumfree medium and exposure to hypoxia (5% CO2,95% N2) for 12 h with or without TMZ.Thirty Wistar rats were divided into 3 groups (n=10 each group),including groupⅠ(AMI control),groupⅡ (MSCs transplantation alone),and group Ⅲ (TMZ+MSCs).Rat MSCs (4×107) were injected into peri-infarct myocardium (MSCs group and TMZ+MSCs group) 30 min after coronary artery ligation.The rats in TMZ+MSCs group were additionally fed on TMZ (2.08 mg?kg-1?day-1) from day 3 before AMI to day 28 after AMI.Cardiac structure and function were assessed by echocardiography at 28th day after transplantation.Blood samples were collected before the start of TMZ therapy (baseline),and 24 and 48 h after AMI,and inflammatory cytokines (CRP,TNF-α) were measured.Then the sur-vival and differentiation of transplanted cells in vivo were detected by immunofluorescent staining.The cellular apoptosis in the peri-infarct region was detected by using TUNEL assay.Furthermore,apoptosis-related proteins (Bcl-2,Bax) within the post-infarcted myocardium were detected by using Western blotting.In hypoxic culture,the TMZ-treated MSCs displayed a two-fold decrease in apoptosis under serumfree medium and hypoxia environment.In vivo,cardiac infarct size was significantly reduced,and cardiac function significantly improved in MSCs and TMZ+MSCs groups as compared with those in the AMI control group.Combined treatment of TMZ with MSCs implantation demonstrated further decreased MSCs apoptosis,further increased MSCs viability,further decreased infarct size,and further improved cardiac function as compared with MSCs alone.The baseline levels of inflammatory cyto-kines (CRP,TNF-α) had no significant difference among the groups.In contrast,all parameters at 24 h were lower in TMZ+MSCs group than those in MSCs group.Furthermore,Western blotting indicated that the expression of antiapoptotic protein Bcl-2 was upregulated,while the proapoptotic protein Bax was down-regulated in the TMZ+MSCs group,compared with that in the MSCs group.It is suggested that implantation of MSCs combined with TMZ treatment is superior to MSCs monotherapy for MSCs viability and cardiac function recovery.
出处 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2012年第1期36-41,共6页 华中科技大学学报(医学英德文版)
基金 supported by grants from the National Natural Science Foundation of China (No. 30700314) Wuhan Science and Technology Bureau of Hubei province,China (No.20065004116-02)
关键词 TRIMETAZIDINE bone marrow mesenchymal stem cells VIABILITY myocardial ischemia trimetazidine bone marrow mesenchymal stem cells viability myocardial ischemia
  • 相关文献

参考文献28

  • 1Ho KK,Anderson KM,Kannel WB. Survival afterthe onset of congestive heart failure in Framingham Heart Study subjects[J].Circulation,1993,(01):107-115.
  • 2Makino S,Fukuda K,Miyoshi S. Cardiomyocytes can be generated from marrow stromal cells in vitro[J].Journal of Clinical Investigation,1999,(05):697-705.
  • 3Song H,Kwon K,Lim S. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survivalunderhypoxicconditions[J].MolCells,2005,(03):402-407.
  • 4Bianchi G,Banff A,Mastrogiacomo M. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2[J].Experimental Cell Research,2003,(01):98-105.
  • 5Mangi AA,Noiseux N,Kong D. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts[J].Nature Medicine,2003,(09):1195-1201.doi:10.1038/nm912.
  • 6Maridonneau PI,Harpey C. Effects of trimetazidine on membrane damage reduced by oxygen free radicals in human red cells[J].British Journal of Clinical Pharmacology,1985,(02):148-151.
  • 7Maupoil V,Rochette L,Tabard A. Direct measurement of free radical generation in isolated rat heart by electron paramagnetic resonance spectroscopy:effect of trimetazidine[J].Advances in Experimental Medicine and Biology,1990.373-376.
  • 8Reymond F,Steyaert G,Carrupt PA. The pH-partitionprofileoftheanti-ischemicdrug trimetazidine may explain its reduction of intracellular acidosis[J].Pharmaceutical Research,1999,(05):616-624.
  • 9Renaud JF. Internal pH,Na+,and Ca2+ regulation by trimetazidine during cardiac cell acidosis[J].Cardiovascular Drugs and Therapy,1988,(06):677-686.
  • 10Salducci MD,Chauvet-Monges AM,Tillement JP. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria[J].Journal of Pharmacology and Experimental Therapeutics,1996,(01):417-422.

同被引文献38

引证文献8

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部